The importance of the level of metronidazole resistance for the success of Helicobacter pylori eradication

Alimentary Pharmacology and Therapeutics

Volumn 19, Issue 12, 2004, Pages 1315-1321

  Wheeldon, T U ^a   Granstrom M ^a   Hoang, T T H ^a,b   Phuncarg, D C ^b   Nilsson, L E ^c   Sorberg M ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b National Institute of Hygiene and Epidemiology   (Viet Nam)

^c LINKÖPING UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; LANSOPRAZOLE; METRONIDAZOLE; PLACEBO; PROTON PUMP INHIBITOR; TETRACYCLINE; TINIDAZOLE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; BACTERIAL STRAIN; CLINICAL TRIAL; CONCENTRATION RESPONSE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ERADICATION THERAPY; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HUMAN; MINIMUM INHIBITORY CONCENTRATION; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; TREATMENT OUTCOME;

2-PYRIDINYLMETHYLSULFINYLBENZIMIDAZOLES; ANTI-BACTERIAL AGENTS; ANTI-ULCER AGENTS; CLARITHROMYCIN; DRUG ADMINISTRATION SCHEDULE; DRUG RESISTANCE, BACTERIAL; DRUG THERAPY, COMBINATION; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; METRONIDAZOLE; MICROBIAL SENSITIVITY TESTS; OMEPRAZOLE; PEPTIC ULCER; PROTON PUMPS; TINIDAZOLE; TREATMENT OUTCOME;

EID: 3042709641     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2004.01959.x     Document Type: Article

References (34)

1. Dixon M, Sobala G. Gastritis and duodenitis: the histopathological spectrum. Eur J Gastroenterol Hepatol 1992; 4: S17-S23.
2. Uemura N, Okamoto S, Yamamoto S, et al. Helicobacter pylori infection and the development of gastric cancer. N Engl J Med 2001; 345: 784-9.
3. Hentschel E, Brandstatter G, Dragosics B, et al. Effect of ranitidine and amoxicillin plus metronidazole on the eradication of Helicobacter pylori and the recurrence of duodenal ulcer. N Engl J Med 1993; 328: 308-12.
4. Sung JJ, Chung SC, Ling TK, et al. Antibacterial treatment of gastric ulcers associated with Helicobacter pylori. N Engl J Med 1995; 332: 139-42.
5. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection - the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002; 16: 167-80.
6. Labenz J, Idstrom JP, Tillenburg B, Peitz U, Adamek RJ, Borsch G. One-week low-dose triple therapy for Helicobacter pylori is sufficient for relief from symptoms and healing of duodenal ulcers. Aliment Pharmacol Ther 1997; 11: 89-93.
7. Bell GD, Powell KU, Burridge SM, et al. Rapid eradication of Helicobacter pylori infection. Aliment Pharmacol Ther 1995; 9: 41-6.
8. Bazzoli F, Zagari R, Fossi S, et al. Short-term low-dose triple therapy for the eradication of Helicobacter pylori. Eur J Gastroenterol Hepatol 1994; 6: 773-777.
9. Laine L, Estrada R, Trujillo M, Emami S. Randomized comparison of ranitidine bismuth citrate-based triple therapies for Helicobacter pylori. Am J Gastroenterol 1997; 92: 2213-5.
10. Murakami K, Sato R, Okimoto T, et al. Eradication rates of clarithromycin-resistant Helicobacter pylori using either rabeprazole or lansoprazole plus amoxicillin and clarithromycin. Aliment Pharmacol Ther 2002; 16: 1933-8.
11. Lind T, Megraud F, Unge P, et al. The MACH2 study: role of omeprazole in eradication of Helicobacter pylori with 1-week triple therapies. Gastroenterology 1999; 116: 248-53.
12. Queiroz DM, Dani R, Silva LD, et al. Factors associated with treatment failure of Helicobacter pylori infection in a developing country. J Clin Gastroenterol 2002; 35: 315-20.
13. Houben MH, van de Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy - the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther 1999; 13: 1047-55.
14. Lerang F, Moum B, Haug JB, et al. Highly effective twice-daily triple therapies for Helicobacter pylori infection and peptic ulcer disease: does in vitro metronidazole resistance have any clinical relevance? Am J Gastroenterol 1997; 92: 248-53.
15. Fock KM, Chelvam P, Lim SG. Triple therapy in the eradication of Helicobacter pylori in patients with duodenal ulcer disease: results of a multicentre study in South-East Asia. South-East Asia Multicenter Study Group. Aliment Pharmacol Ther 2000; 14: 225-31.
16. Moayyedi P, Ragunathan PL, Mapstone N, Axon AT, Tompkins DS. Relevance of antibiotic sensitivities in predicting failure of omeprazole, clarithromycin, and tinidazole to eradicate Helicobacter pylori. J Gastroenterol 1998; 33(Suppl. 10): 62-5.
17. van der Wouden EJ, Thijs JC, van Zwet AA, Sluiter WJ, Kleibeuker JH. The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis. Am J Gastroenterol 1999; 94: 1751-9.
18. Prazeres Magalhaes P, De Magalhaes Queiroz DM, Campos Barbosa DV, et al. Helicobacter pylori primary resistance to metronidazole and clarithromycin in Brazil. Antimicrob Agents Chemother 2002; 46: 2021-3.
19. Osato MS, Reddy R, Graham DY. Metronidazole and clarithromycin resistance amongst Helicobacter pylori isolates from a large metropolitan hospital in the United States. Int J Antimicrob Agents 1999; 12: 341-7.
20. Glupczynski Y, Megraud F, Lopez-Brea M, Andersen LP. European multicentre survey of in vitro antimicrobial resistance in Helicobacter pylori. Eur J Clin Microbiol Infect Dis 2001; 20: 820-3.
21. Ani AE, Malu AO, Onah JA, Queiroz DM, Kirschner G, Rocha GA. Antimicrobial susceptibility test of Helicobacter pylori isolated from Jos, Nigeria. Trans R Soc Trop Med Hyg 1999; 93: 659-61.
22. Wu H, Shi XD, Wang HT, Liu JX. Resistance of Helicobacter pylori to metronidazole, tetracycline and amoxycillin. J Antimicrob Chemother 2000; 46: 121-3.
23. Wheeldon TU, Hoang TT, Phung DC, Bjorkman A, Granstrom M, Sorberg M. Helicobacter pylori eradication and peptic ulcer healing: the impact of deleting the proton pump inhibitor and using a once-daily treatment. Aliment Pharmacol Ther 2003; 18: 93-100.
24. Svensson M, Nilsson M, Ström M, Sörberg M, Nilsson LE. Do combinations with nitroimidazoles or amoxicillin prevent development of clarihromycin resistance in Helicobacter pylori? Gut 1999; 45.
25. Buckley MJ, Xia HX, Hyde DM, Keane CT, O'Morain CA. Metronidazole resistance reduces efficacy of triple therapy and leads to secondary clarithromycin resistance. Dig Dis Sci 1997; 42: 2111-5.
26. Heep M, Kist M, Strobel S, Beck D, Lehn N. Secondary resistance among 554 isolates of Helicobacter pylori after failure of therapy. Eur J Clin Microbiol Infect Dis 2000; 19: 538-41.
27. Megraud F, Lehn N, Lind T, et al. Antimicrobial susceptibility testing of Helicobacter pylori in a large multicenter trial: the MACH 2 study. Antimicrob Agents Chemother 1999; 43: 2747-52.
28. van der Hulst RW, Rauws EA, Koycu B, et al. Helicobacter pylori reinfection is virtually absent after successful eradication. J Infect Dis 1997; 176: 196-200.
29. Fraser AG, Schreuder V, Chua LE, Moore L. Follow up after successful eradication of Helicobacter pylori: symptoms and reinfection. J Gastroenterol Hepatol 1998; 13: 555-9.
30. Bell GD, Powell KU. Helicobacter pylori reinfection after apparent eradication - the Ipswich experience. Scand J Gastroenterol Suppl 1996; 215: 96-104.
31. Mitchell HM, Hu P, Chi Y, Chen MH, Li YY, Hazell SL. A low rate of reinfection following effective therapy against Helicobacter pylori in a developing nation (China). Gastroenterology 1998; 114: 256-61.
32. Hildebrand P, Bardhan P, Rossi L, et al. Recrudescence and reinfection with Helicobacter pylori after eradication therapy in Bangladeshi adults. Gastroenterology 2001; 121: 792-8.
33. Ramirez-Ramos A, Gilman RH, Leon-Barua R, et al. Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication. Gastrointestinal Physiology Working Group of the Universidad Peruana Cayetano Heredia and The Johns Hopkins University. Clin Infect Dis 1997; 25: 1027-31.
34. Soto G, Bautista CT, Roth DE, et al. Helicobacter pylori reinfection is common in Peruvian adults after antibiotic eradication therapy. J Infect Dis 2003; 188; 1263-75.